{"id":112,"date":"2020-04-27T04:29:08","date_gmt":"2020-04-27T04:29:08","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=112"},"modified":"2020-05-12T05:28:00","modified_gmt":"2020-05-12T05:28:00","slug":"23-april-2020-baricitinib-none-of-the-baricitinib-treated-patients-required-admission-to-icu","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/23-april-2020-baricitinib-none-of-the-baricitinib-treated-patients-required-admission-to-icu\/","title":{"rendered":"(23 April 2020) Baricitinib- none of the baricitinib-treated patients required admission to ICU"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact<\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7177073\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7177073\/<\/a><\/p>\n<p class=\"\">Baricitinib at 4 mg\/day\/orally was given to 12 patients with moderate COVID-19. &nbsp;In baricitinib-treated patients no adverse events were recorded and clinical and respiratory parameters significantly improved in 2 weeks. None of the baricitinib-treated patients required admission to ICU.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7177073\/ Baricitinib at 4 mg\/day\/orally was given to 12 patients with moderate COVID-19. &nbsp;In baricitinib-treated patients no adverse events were recorded and clinical and respiratory parameters significantly improved&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/23-april-2020-baricitinib-none-of-the-baricitinib-treated-patients-required-admission-to-icu\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(23 April 2020) Baricitinib- none of the baricitinib-treated patients required admission to ICU&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[21,4],"tags":[45],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/112"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=112"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/112\/revisions"}],"predecessor-version":[{"id":113,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/112\/revisions\/113"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}